Avac Event

Embracing Task Shifting and Innovation to Support Expanded Access to Long-Acting Injectable PrEP

While the HIV prevention buffet will soon offer a second form of long acting injectable PrEP, ensuring access to all those who can benefit requires innovations in service delivery such as task shifting. In the United States, two Federally Qualified Health Centers (FQHCs) have implemented programming that has expanded clinic capacity, resulting in more individuals being able to choose long acting injectable PrEP. We also heard about innovative efforts to expand PrEP access in South Africa and learned what it takes to integrate task shifting for long-acting PrEP injection programs. We discussed other ways we can collectively innovate to support expanded, sustainable access to all forms of PrEP.

Speakers:

  • Kevin Aloysius, Legacy Community Health, Houston
  • Megan Dieterich, Whitman-Walker Health, Washington, DC
  • Juan Carlos Loubriel, Whitman-Walker Health, Washington, DC
  • Carey Pike, Desmond Tutu Health Foundation, Cape Town

Moderator:

  • Rupa Patel, Washington University in St. Louis

Materials:

Press Release

AVAC Condemns Removal of the Advisory Committee on Immunization Practices

Contact: [email protected]

NEW YORK, NY, June 11, 2025—AVAC strongly condemns Secretary of Health and Human Services, Robert F. Kennedy, Jr., for removing all members of the Advisory Committee on Immunization Practices (ACIP). This committee of vaccine experts—with decades of experience in vaccine development, delivery and safety—is responsible for developing the country’s vaccine policies and recommendations for the Centers for Disease Control and Prevention (CDC). At a time when science is under political attack and vital programs are being defunded, AVAC stands with researchers, advocates, and communities calling for Congress to defend public health and unbiased science, which is essential to safeguarding the health of all Americans. The Secretary’s actions attack the integrity of ACIP membership and is a direct threat to public trust in our health systems and in the essential role of vaccines in disease prevention.

“Vaccines remain among the most powerful public health tools ever developed,” said Mitchell Warren, executive director of AVAC. “Vaccines have transformed the global response to infectious diseases, from smallpox to measles to COVID-19, and they are central to the vision of ending the HIV epidemic. At a moment when the US should be investing more in vaccine science, access, and public confidence, it is investing less and simultaneously undermining vaccines generally. Secretary Kennedy’s short-sighted and unceremonious removal of all ACIP members is an alarming escalation in this administration’s campaign to dismantle evidence-based health policy, science and research.”

ACIP’s long-standing commitment to base vaccine recommendations purely on the evidence represents the highest standards of ethical guidance to protect human health. The Secretary’s decision undermines not just US vaccine strategy, but global confidence in immunization programs and guidance that have long relied on US leadership.

The destruction of ACIP adds to the five-month litany of assaults on vaccines and the systems that support them.  From proposed cuts to the Fiscal Year 2026 budget, to the defunding for global vaccine access programs like Gavi and domestic immunization initiatives at the US CDC, to the undermining of the essential role of measles vaccines, the closure of the leading NIH-funded HIV vaccine consortia (CHAVD), to the dismantling of USAID’s HIV vaccine R&D programs and the recommendation to remove COVID-19 vaccines from the US immunization schedule for children and pregnant women, this administration has worked to subvert the importance and impact of life-saving vaccines and erode public trust for vaccine science.   

Vaccines work. Human papillomavirus (HPV) is responsible for 99% of cervical cancers. The HPV vaccine prevents over 90% of cancers caused by HPV, including anal, cervical, penile, throat, vaginal, and vulvar globally, and if more widely available, could prevent hundreds of thousands of annual deaths, according to the WHO. Similarly, hepatitis B (HBV) accounts for 1.1 million deaths globally, and yet the HBV vaccine prevents as many deaths every year, according to WHO. Furthermore, without a vaccine review panel, rollout of anticipated vaccines that protect against gonorrhea, could make access difficult for many Americans when drug resistant gonorrhea is on the rise globally.

“We are witnessing other countries eliminate cervical cancer through robust HPV vaccination and screening programs while the US risks reversing decades of progress,” says Alison Footman, AVAC’s senior program manager of STIs. “The ACIP plays a critical role in ensuring vaccines, including those that prevent STIs like HPV and hepatitis B, are accessible, and recommendations are guided by expert opinions. Now more than ever, we must protect the integrity of public health systems that save lives and prevent diseases.”

As public confidence in vaccines erodes, the value of vaccine science is paramount, representing one of the single greatest advances in the history of medical science, eradicating once life-threatening infections and mitigating the risk of illness from numerous diseases. In the field of HIV, the search for an effective vaccine is advancing thanks to decades of investment in basic science, clinical research, and global partnerships. This progress must be protected and accelerated. A vaccine would provide a durable, scalable form of HIV prevention that does not rely on frequent adherence or health system access, and it would be especially transformative for communities most marginalized by current systems.

AVAC calls on Congress, scientists, and civil society to speak out and stand up for science, for vaccines, and for the future of global and public health.

###

About AVAC

AVAC is an international non-profit organization that provides an independent voice and leverages global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity. Follow AVAC on Bluesky and Instagram. Find more at www.avac.org and www.prepwatch.org.

Avac Event

World Health Assembly-A new era of HIV prevention; Accelerating access to long-acting prevention options through sustainable prevention systems and financing

This High-Level Dialogue organized by the Global HIV Prevention Coalition and co-hosted by UNAIDS in collaboration with UNFPA, WHO and UNDP, the Federal Republic of Brazil and Kingdom of the Netherlands aims to galvanize political leadership, financing, and coordinated action to drive a transformational HIV prevention push. The meeting will serve as a platform for Ministers of Health, global health partners, pharmaceutical companies, and civil society to explore opportunities to expand access to new long-acting prevention technologies as a powerful addition to existing effective options.

Join Mitchell Warren as he chairs the discussion alongside UNAIDS leadership, representatives of UN partners and global health stakeholders.

HIV Prevention R&D at Risk

Tracking the Impact of US Funding Cuts

The US presidential administration is actively working to dismantle HIV research and demolish the architecture of global health. The entire HIV response — from basic research and clinical development to policy, programs, and global access to life-saving treatment and prevention — is now under attack, and the world runs the risk of reversing the strides made to end HIV.

AVAC has put together this report, highlighting the impact of US cuts on the pipeline of HIV prevention research and development. AVAC will continue to track these cuts and their impact, to amplify the damage they will cause, and to fight for their reversal.

Avac Event

WHO-Lancet Global Health Series: Shaping the Future of Clinical Trials

WHO and partners will convene to launch the Lancet Global health series: Shaping the Future of Clinical Trials. Details and registration link below.

FAPP Response to NIH Cuts to Indirect Research Costs

Federal AIDS Policy Partnership Research Working Group urges Congressional leaders to support the restraining order preventing the National Institutes of Health (NIH) from unlawfully stripping funds that sustain cutting-edge medical and public health research at universities and research institutions nationwide. Read the full letter.

Avac Event

Introducing the Dual Prevention Pill: Lessons Learned and What’s Next for Regulatory, Research, and Rollout

This webinar has been cancelled because funding was pulled by the new US administration. Follow critical developments in US policies and their impact on global health via our new newsletter. Learn more here.

Join the IMPT and guest speakers from AVAC and Population Council for a discussion on the dual prevention pill (DPP)—a single pill that combines oral pre-exposure prophylaxis (PrEP) and oral contraception (OC) to prevent HIV and pregnancy. If approved, the DPP will be the first multi-purpose prevention technology (MPT) to be marketed since condoms.

The discussion will include real-time learnings to inform the broader MPT field on the DPP’s regulatory approval process, acceptability study results in South Africa and Zimbabwe, implementation updates, and lessons learned. 

There will be a Q&A session following the presentations.

AVAC’s Most Downloaded Resources of 2024

From the implementation of DoxyPEP to the game-changing trial results of lenacapavir for PrEP, 2024 has been a landmark year for advancements in HIV and STI prevention. AVAC’s most downloaded resources capture these pivotal milestones, offering essential insights and tools to power your advocacy. Dive into the highlights and stay informed about the strategies shaping the future of HIV prevention.


AVAC’s Top 10

This episode of PxPulse looks at why and how the decisions that shape global health must be made by those facing the greatest risks. As the world evaluates the pandemic response and debates on decolonizing global health gain momentum, equity in global health has never been more urgent.

This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.

This plan provides a broad view of all the moving parts and identifies actions and actors responsible for ensuring time is not wasted and opportunity not squandered.

This PxPulse podcast episode goes deep on LEN for PrEP. Recorded just days before Gilead’s announcement that PURPOSE 2 also found very high efficacy, Dr. Flavia Kiweewa, a principal investigator of the first trial to announce efficacy, lays out the research findings and what they mean. And Chilufya Kasanda Hampongo of Zambia’s Treatment Advocacy and Literacy Campaign and Mitchell Warren of AVAC talk about how to change a long history of squandered opportunities to get rollout right.

This report examines disbursements by the U.S. NIH and the Bill & Melinda Gates Foundation and is one of few reports to track funding trends in vaccine and diagnostics R&D, and pipeline investments for some of the most common STIs.

Led by AVAC alongside a network of partners, the People’s Research Agenda puts forward recommendations to diversify and strengthen the HIV prevention pipeline, enhance investment and financial support for HIV prevention research and development, and guide an advocacy strategy that truly addresses the needs of communities across the prevention pipeline.

This roadmap aims to build on existing progress while accelerating the pace of HIV prevention. With anticipated regulatory approvals and production scaling, this plan targets over 2.5 million LEN users in low- and middle-income countries by 2027. It focuses on structural barriers and integration of generics into national programs.

Good Participatory Practice Guidelines  have been shaping and improving clinical research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.

DoxyPEP is a post-exposure prophylaxis used to prevent the acquisition of some bacterial STIs after sex. This advocates’ guide addresses questions regarding who will benefit most from DoxyPEP and how to implement this strategy broadly to ensure equitable access.

In 2024, Gilead Sciences released findings from the PURPOSE 1 and PURPOSE 2 trials testing lenacapavir (LEN) as HIV prevention. This advocates’ primer provides background on the product and trials; a summary of the early findings of PURPOSE 1 & 2; key questions and next steps.

Avac Event

Conference on Retroviruses and Opportunistic Infections 2025

The 32nd annual  Conference on Retroviruses and Opportunistic Infections (CROI) that took place from March 9–12 in San Francisco, CA convened researchers, advocates and others under drastically altered circumstances, as the new US Administration’s assault on global health and research devastates the HIV response. Foreign aid programs are frozen, US agencies championing science and global health are being dismantled, and US leadership around the world is receding at a critical moment.

Read our summaries:

View our Community Breakfast Clubs

The CROI Community Liaisons, AVAC and the  European AIDS Treatment Group organized a series of daily  Community Breakfast Clubs which were open to all. These live webinars featured researchers and advocates exploring some of the most consequential science and discussions from CROI.

Topics included:

  • Breaking New Ground: The latest advances in HIV cure
  • The End of AIDS — Near and Far? (40 Years of HIV)
  • Still Here! Living with HIV Long-Term

Avac Event

African Workshop on HIV & Women 2025

The inaugural edition of the African Workshop on HIV & Women will take place in hybrid format on 27 – 28 February 2025 in Nairobi, Kenya.

The time zone that will be used for this meeting is East Africa Time (EAT). If you need to convert the times to your timezone, this website might be of interest to you: www.WorldTimeBuddy.com.

This exciting new initiative is a regional workshop paired to the annual “International Workshop on HIV & Women”. It is an outstanding opportunity for both local and international healthcare providers, researchers, government, industry, and community representatives to discuss and further increase their knowledge on the issues related to HIV and women living in Africa.

The primary purpose of this workshop is to support changes that will provide a better quality of life for women living with HIV and reduce HIV transmissions in the region.

The format of the workshop enables attendees to learn from renowned HIV experts, discuss challenges, gaps, and opportunities for further learning and research. The debates and roundtables are an especially important vehicle to discuss issues and challenge dogma.

The workshop also provides a forum for early-career investigators to present their research and to personally meet with experts they view as mentors and inspiration for their work.

The meeting organizers hope this workshop will catalyze forming a community, where attendees continue to participate yearly and form valuable relationships and partnerships that lead to collaborative projects and positive changes.